Compare FSBW & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FSBW | ENGN |
|---|---|---|
| Founded | 1936 | 1999 |
| Country | United States | Canada |
| Employees | 537 | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.6M | 117.2M |
| IPO Year | 2011 | 2023 |
| Metric | FSBW | ENGN |
|---|---|---|
| Price | $43.29 | $1.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $46.00 | $21.08 |
| AVG Volume (30 Days) | 13.8K | ★ 798.2K |
| Earning Date | 04-21-2026 | 06-11-2026 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | N/A | ★ 56.85 |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $4,612,000.00 | N/A |
| Revenue This Year | $14.94 | N/A |
| Revenue Next Year | $10.47 | N/A |
| P/E Ratio | $20.81 | ★ N/A |
| Revenue Growth | ★ 44.80 | N/A |
| 52 Week Low | $36.85 | $1.40 |
| 52 Week High | $45.85 | $12.25 |
| Indicator | FSBW | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.68 | 53.40 |
| Support Level | $41.09 | $1.67 |
| Resistance Level | $43.75 | $1.96 |
| Average True Range (ATR) | 0.87 | 0.08 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 59.83 | 65.05 |
FS Bancorp Inc is the holding company of First Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.